NCT05484557

Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Loewenstein Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI (rehabilitation) will be given either Enoxaparin 40 mg/day (control) or Apixaban 2.5-5 mg twice a day. Apixaban dose will be determined by the treating physician. Treatment will be continued for either 6 or 12 weeks following injury (for AIS grades C-D and A-B respectively). Endpoints: Venous thromboembolism will be evaluated by D-Dimer test every 2 weeks and an ultrasound doppler at the beginning and the end of the treatment. Bleeding events will be recorded and hematocrit will be monitored every two weeks.

Conditions

• Spinal Cord Injuries
• Spinal Diseases

Interventions

Type	Name	Description
DRUG	Apixaban	treatment for 6 to 12 weeks
DRUG	Enoxaparin Sodium	treatment for 6 to 12 weeks

Timeline

• Start date: 2023-09-06
• Primary completion: 2025-08-01
• Completion: 2026-02-01
• First posted: 2022-08-02
• Last updated: 2025-05-09

Locations

1 site across 1 country: Israel